Structure Therapeutics (NASDAQ:GPCR) Hits New 52-Week Low – Here’s Why

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) reached a new 52-week low during mid-day trading on Friday . The company traded as low as $19.11 and last traded at $19.16, with a volume of 42940 shares trading hands. The stock had previously closed at $19.94.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on GPCR shares. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. Stifel Nicolaus began coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price target on the stock. William Blair started coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They issued an “outperform” rating on the stock. Finally, JMP Securities reissued a “market outperform” rating and issued a $91.00 target price on shares of Structure Therapeutics in a report on Wednesday, December 18th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Trading Down 3.4 %

The stock has a market cap of $1.10 billion, a P/E ratio of -25.78 and a beta of -2.37. The business’s fifty day simple moving average is $24.34 and its 200 day simple moving average is $31.35.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. On average, analysts predict that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of Montreal Can increased its stake in shares of Structure Therapeutics by 71.6% in the 3rd quarter. Bank of Montreal Can now owns 46,502 shares of the company’s stock valued at $1,941,000 after acquiring an additional 19,408 shares during the last quarter. FMR LLC raised its holdings in Structure Therapeutics by 6.7% in the third quarter. FMR LLC now owns 6,128,444 shares of the company’s stock worth $268,977,000 after purchasing an additional 383,635 shares during the period. Vestal Point Capital LP boosted its position in shares of Structure Therapeutics by 105.4% during the third quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock worth $50,474,000 after purchasing an additional 590,000 shares in the last quarter. Verition Fund Management LLC grew its holdings in shares of Structure Therapeutics by 15.3% in the 3rd quarter. Verition Fund Management LLC now owns 16,703 shares of the company’s stock valued at $733,000 after buying an additional 2,218 shares during the period. Finally, Point72 Europe London LLP grew its holdings in shares of Structure Therapeutics by 156.8% in the 3rd quarter. Point72 Europe London LLP now owns 44,833 shares of the company’s stock valued at $1,968,000 after buying an additional 27,378 shares during the period. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.